Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study.

Phunchai CharatcharoenwitthayaVirasak WongpaitoonPiyawat KomolmitWattana SukeepaisarnjaroenPisit TangkijvanichTeerha PiratvisuthTheeranun SanpajitChinnavat SutthivanaChalermrat BunchorntavakulAbhasnee SobhonslidsukSoonthorn ChonprasertsukChotipong SiripipattanamongkolSupatsri SethasineTawesak Tanwandeenull null

Published in: BMC gastroenterology (2020)

In this large cohort of patients with various HCV genotypes managed in the real-world practice setting, daclatasvir plus sofosbuvir, ledipasvir/sofosbuvir, and sofosbuvir/velpatasvir achieved high SVR rates with good safety profile, comparable to those observed in clinical trials.

Keyphrases

hepatitis c virus
human immunodeficiency virus
clinical trial
hepatitis c virus infection
primary care
healthcare
randomized controlled trial
protein protein
cross sectional
binding protein
liver fibrosis
combination therapy
hiv infected